PARIS — Two landmark clinical trials reported today at the Union meeting showed that an oral antibiotic taken for six months once-daily substantially reduced the risk of developing drug-resistant TB. The antibiotic levofloxacin safely reduced the risk of multidrug-resistant (MDR) tuberculosis (TB) disease in children by 56%, researchers from the...
Latest News
Pittsburgh, PA – Two studies published in the latest issue of the journal Cell by University of Pittsburgh researchers uncover how immunotherapies targeting the immune checkpoints PD1 and LAG3 work together to activate immune responses. The findings shed light on why combination therapies targeting both checkpoints can improve outcomes for...
Bochum, Germany – A research team from the Department of Medical and Molecular Virology at Ruhr University Bochum monitored and treated two patients with chronic hepatitis E with a combination of sofosbuvir and ribavirin after they had not previously responded to ribavirin alone. “In both cases, the combination therapy was...
Stockholm, Sweden – There does not appear to be any profound differences between so-called exposure-based CBT and traditional CBT in the treatment of fibromyalgia, according to a study led by researchers at Karolinska Institutet. Both forms of treatment produced a significant reduction in symptoms in people affected by the disease....
Recall the saying “there are a thousand ways to skin a cat”? Researchers are rephrasing it in regard to the mosquito. Fifty years ago, we thought that the war against malaria was pretty much won. We had quinine and chloroquine, which were effective against the parasite that causes the disease....
ORLANDO — Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are...
EL PASO — Two-year-old Emmanuel Gonzalez felt the sun on his face for the first time in weeks Sunday. He has a rare immune system disorder and had to stay in his room at Providence Memorial Hospital while he got well enough to make his first trip down to the...
BIRMINGHAM, Ala. – Researchers have discovered the novel mechanism that underlies a previously reported observation that infection by group A Streptococcus bacteria reduces the risk of later developing Type 1 diabetes. The Journal of Immunology reports that vaccination of neonatal mice with group A Streptococcus promoted a clonal expansion of...
CARLSBAD, Calif. — Tyra Biosciences, Inc. a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it has initiated the SURF201 Phase 1 study of TYRA-200 and provided positive updates on its oral FGFR3-selective inhibitor, TYRA-300....
CARLSBAD, Calif. — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300, an oral...